| 1.33 -0.075 (-5.34%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.84 |
1-year : | 2.04 |
| Resists | First : | 1.57 |
Second : | 1.75 |
| Pivot price | 1.55 |
|||
| Supports | First : | 1.29 |
Second : | 1.08 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 1.55 |
| MA(100) : | 1.76 |
MA(250) : | 2.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 34.1 |
| RSI | RSI(14): 30.9 |
|||
| 52-week | High : | 3.48 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PROK ] has closed below the lower bollinger band by 10.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PROK ] is to continue within current trading range. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.44 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.31 - 1.33 | 1.33 - 1.34 |
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Fri, 14 Aug 2026
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
Wed, 12 Aug 2026
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
Wed, 12 Aug 2026
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into Focus - Profit Surge Picks - dars.gov.et
Mon, 10 Aug 2026
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com
Mon, 10 Aug 2026
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
Fri, 24 Jul 2026
ProKidney (NASDAQ:PROK) Trading Down 0.7% - Time to Sell? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 1.5676e+008 (%) |
| Held by Institutions | 47.2 (%) |
| Shares Short | 17,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6192e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -19 % |
| Return on Assets (ttm) | 881.8 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 889000 % |
| Gross Profit (p.s.) | -0.99 |
| Sales Per Share | -28.71 |
| EBITDA (p.s.) | 516860 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 2.091e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|